Released Feb 26, 2026, before the open
10-K filed Feb 26, 2026, 57 days after period end · 0001193125-26-073699
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.37M$1.37M derived−26.4% vs Q4 2024−21.4% vs Q3 2025
Net Income-$32.37M-$32.37M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$34,721,000N/M
Operating Cash Flowderived-$23,314,000N/M
Free Cash Flowderived-$24,506,000N/M
Margins · derived
Operating margin-2536.2%+783.6 pt vs Q4 2024
Net margin-2364.8%+439.1 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.37M | $1.86M | $1.68M | $44.36M |
| Net Income | -$32.37M | -$52.15M | -$44.12M | -$56.36M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR